BTIG Maintains Buy on Innate Pharma, Raises Price Target to $9
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
BTIG analyst Jeet Mukherjee maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $8 to $9.
BTIG analyst Jeet Mukherjee maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $8 to $9.